Experience with community-based amphotericin B infusion therapy

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 690-697

  Malani, Preeti N ^a,c   DePestel, Daryl D ^b,d   Riddell IV, James ^a   Bickley, Susan ^b,d   Klein, Lisa R ^b,d   Kauffman, Carol A ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adverse effects; Amphotericin B; Community based therapy; Monitoring; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN; TACROLIMUS;

ADOLESCENT; ADULT; AGED; CHILD; CHILL; COMMUNITY CARE; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEVICE INFECTION; DEVICE REMOVAL; DRUG INFUSION; DRUG MONITORING; DYSPNEA; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; NEPHROTOXICITY; NEWBORN; REVIEW; THORAX PAIN; UREA NITROGEN BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG CARRIERS; FEMALE; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS, UNIVERSITY; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 18044389505     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.690.63591     Document Type: Review

References (26)

1. Rehm SJ, Weinstein AJ. Home intravenous antibiotic therapy: a team approach. Ann Intern Med 1983;99:388-92.
2. Rehm SJ, Longworth DL. Rates of adverse events associated with community-based parenteral anti-infective therapy. J Clin Outcomes Manage 2000;7:23-8.
3. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261-8.
4. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve endocarditis. Clin Infect Dis 2001;33:203-9.
5. Gilbert DN, Dworkin RJ, Raber SR, Leggett JE. Outpatient parenteral antimicrobial drug therapy. N Engl J Med 1997;337:829-38.
6. Tice AD, Rehms SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004;38:1651-72.
7. Hoffman-Terry ML, Fraimow HS, Fox TR, Swift BG, Wolf JE. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med 1999;106:44-9.
8. Chemaly RF, de Parres JB, Rehm SJ, et al. Venous thrombosis associated with peripherally inserted central catheters: a retrospective analysis of the Cleveland Clinic experience. Clin Infect Dis 2002;34:1179-83.
9. Kauffman CA. Ampholericin B. Sem Respir Crit Care Med 1997;18:281-7.
10. Gallis HA, Drew RA, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
11. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
12. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
13. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
14. Bates DW, Su L, Yu T, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93.
15. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999;43:267-71.
16. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-34.
17. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
18. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
19. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71.
20. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold" standard. Clin Infect Dis 2003;37:415-25.
21. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
22. Branch RA. Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
23. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75:476-81.
24. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002;186:379-88.
25. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
26. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-57.